FDA Determines Regulatory Review Period for CERVARIX Patent Extension

Summary

The FDA has published a notice determining the regulatory review period for CERVARIX, a human biological product, in response to a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.